These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2675480)

  • 1. [Leakage measurements with the dye extraction method and direct methotrexate level determination (enzyme immunoassay) during and after regional cytostatic limb perfusion].
    Krauss J; Krause G; Hellthaler G
    Z Exp Chir Transplant Kunstliche Organe; 1989; 22(4):260-3. PubMed ID: 2675480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dye concentration measurements for the determination of leakage during and following normothermic cytostatic perfusion in the treatment of tumors of the extremities].
    Krauss J; Lange U; Pauer HD; Krauss I
    Z Exp Chir Transplant Kunstliche Organe; 1984; 17(5):269-74. PubMed ID: 6095550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dye dilution test to determine leakage during regional perfusion in the treatment of malignant tumors of the extremities].
    Ghussen F; Isselhard W; Sturz J; Welte CP; Stock W; Müller EW
    Chir Forum Exp Klin Forsch; 1979; ():165-8. PubMed ID: 378584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of regional therapy: isolated limb infusion and other low flow techniques for extremity melanoma.
    Kam PC; Thompson JF
    Surg Oncol Clin N Am; 2008 Oct; 17(4):795-804, ix. PubMed ID: 18722919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [O2 utilization during hyperthermic extremity perfusion with rhTNF alpha and melphalan].
    Haier J; Hohenberger P; Beck K; Schlag PM
    Langenbecks Arch Chir; 1997; 382(3):128-33. PubMed ID: 9324610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regional cytostatic perfusion of the extremities in patients with malignant melanoma and soft tissue sarcoma--therapeutic applications and results].
    Eichfeld U; Gläser A; Schneider G; Kraus J; Pauer HJ; Schwarz I
    Zentralbl Chir; 1993; 118(2):63-8. PubMed ID: 7682024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated regional limb hyperthermic perfusion as treatment for melanoma.
    Loescher LJ; Leigh S
    Cancer Nurs; 1984 Dec; 7(6):461-7. PubMed ID: 6568866
    [No Abstract]   [Full Text] [Related]  

  • 8. Malignant melanoma and isolated limb perfusion.
    Giraud RM
    S Afr J Surg; 1984; 22(4):243-8. PubMed ID: 6523302
    [No Abstract]   [Full Text] [Related]  

  • 9. [Locoregional recurrence of melanomas of the extremities after hyperthermic extremity perfusion: is reperfusion of value?].
    Meyer T; Göhl J; Hohenberger W
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1452-4. PubMed ID: 9931909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. History of regional chemotherapy for cancer of the extremities.
    Ariyan CE; Brady MS
    Int J Hyperthermia; 2008 May; 24(3):185-92. PubMed ID: 18392997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
    Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
    J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models.
    Eggermont AM
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1357-70. PubMed ID: 8854755
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of melanoma in-transit metastases confined to the limb.
    Eggermont AM
    Cancer Surv; 1996; 26():335-49. PubMed ID: 8783582
    [No Abstract]   [Full Text] [Related]  

  • 14. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
    Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
    Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma.
    Fraker DL; Alexander HR
    Important Adv Oncol; 1994; ():179-92. PubMed ID: 8206489
    [No Abstract]   [Full Text] [Related]  

  • 18. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated limb perfusion for malignant melanoma.
    Rosin RD; Westbury G
    Practitioner; 1980 Oct; 224(1348):1031-6. PubMed ID: 7220430
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
    Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
    Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.